fashion -WSS

fashion

author：hotspot 2025-09-28 23:49:38 - browse：2979

Illustration of researchers working among oversized pill bottles, lab equipment, and medicine for story about the development of obesity medications – health and pharma coverage from STAT — Molly Ferguson for STAT

The exploding popularity of drugs like Wegovy and Mounjaro has propelled dozens of companies to develop their own obesity treatments, with most of them trying to emulate the same approach as the blockbuster products.

Nearly 70 obesity treatments are in development, and about two-thirds use a similar mechanism as Wegovy and Mounjaro, according to the STAT Obesity Drug Tracker, a new database compiled by STAT. There are also a minority of companies pursuing entirely different approaches, hoping that they will stand out among the field.

The tracker, which will be updated with significant developments each quarter, gives a sense of what new mechanisms could hit the market, how they would be delivered, and which companies are running the most trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： The Pandemic Treaty must support building strong health systems

WSS

Wegovy improves function in certain heart failure patients

FDA advisory panel to debate high blood pressure devices

As obesity drug market grows, telehealth companies court payers

FDA greenlights medical device to combat bladder issues

CDC says it’s too soon to assess risk posed by Covid subvariant

Letters to First Opinion on caregivers, digital health, and more

knowledge

fashion

entertainment

In Memoriam: Notable people who died in 2023

Health officials lay out plans to cope with respiratory virus season

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

CDC says it’s too soon to assess risk posed by Covid subvariant

How one medical school became remarkably diverse

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

United colonoscopy coverage change 'may cost lives,' doctors say

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Activists slam private health insurers over coverage restrictions

NIH documents show early flaws of $1.6 billion long Covid program

focus

CDC says it’s too soon to assess risk posed by Covid subvariant

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Change Healthcare can notify patients about the breach, HHS says

Change Healthcare can notify patients about the breach, HHS says

FDA advisory panel to debate high blood pressure devices

entertainment

focus

entertainment

hotspot